Market Closed -
BME
11:35:18 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
9.328
EUR
|
+1.46%
|
|
+1.79%
|
-39.64%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,760
|
14,161
|
9,783
|
6,557
|
9,231
|
5,639
|
-
|
-
|
Enterprise Value (EV)
1 |
25,225
|
20,597
|
16,478
|
15,716
|
18,568
|
14,972
|
14,444
|
13,947
|
P/E ratio
|
34.5
x
|
26.5
x
|
62.5
x
|
34.7
x
|
172
x
|
12.8
x
|
8.52
x
|
7.18
x
|
Yield
|
1.15%
|
0.71%
|
2.13%
|
-
|
-
|
0.49%
|
2.69%
|
4.96%
|
Capitalization / Revenue
|
3.68
x
|
2.65
x
|
1.98
x
|
1.08
x
|
1.4
x
|
0.79
x
|
0.74
x
|
0.69
x
|
EV / Revenue
|
4.95
x
|
3.86
x
|
3.34
x
|
2.59
x
|
2.82
x
|
2.1
x
|
1.9
x
|
1.72
x
|
EV / EBITDA
|
17.9
x
|
13.9
x
|
17.1
x
|
12.9
x
|
12.8
x
|
8.31
x
|
6.8
x
|
6.07
x
|
EV / FCF
|
161
x
|
25.7
x
|
52.1
x
|
-56.7
x
|
-213
x
|
27.3
x
|
23
x
|
15.9
x
|
FCF Yield
|
0.62%
|
3.9%
|
1.92%
|
-1.76%
|
-0.47%
|
3.66%
|
4.34%
|
6.29%
|
Price to Book
|
4.46
x
|
1.99
x
|
1.89
x
|
1.19
x
|
1.79
x
|
0.93
x
|
0.84
x
|
0.76
x
|
Nbr of stocks (in thousands)
|
684,135
|
684,540
|
682,484
|
678,911
|
678,665
|
679,092
|
-
|
-
|
Reference price
2 |
31.43
|
23.88
|
16.88
|
10.77
|
15.46
|
9.328
|
9.328
|
9.328
|
Announcement Date
|
2/27/20
|
2/26/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5,099
|
5,340
|
4,933
|
6,064
|
6,592
|
7,113
|
7,615
|
8,122
|
EBITDA
1 |
1,407
|
1,479
|
961.5
|
1,221
|
1,455
|
1,802
|
2,123
|
2,297
|
EBIT
1 |
1,131
|
996.1
|
595.1
|
805.7
|
1,023
|
1,242
|
1,590
|
1,703
|
Operating Margin
|
22.19%
|
18.65%
|
12.06%
|
13.29%
|
15.52%
|
17.47%
|
20.88%
|
20.97%
|
Earnings before Tax (EBT)
1 |
817.1
|
878.6
|
350.5
|
361.3
|
224
|
887.9
|
1,195
|
1,343
|
Net income
1 |
625.1
|
618.5
|
182.8
|
208.3
|
59.32
|
432.4
|
708.8
|
823.5
|
Net margin
|
12.26%
|
11.58%
|
3.71%
|
3.43%
|
0.9%
|
6.08%
|
9.31%
|
10.14%
|
EPS
2 |
0.9100
|
0.9000
|
0.2700
|
0.3100
|
0.0900
|
0.7272
|
1.095
|
1.299
|
Free Cash Flow
1 |
156.6
|
802.2
|
316.1
|
-277.4
|
-87.14
|
548.7
|
627
|
876.8
|
FCF margin
|
3.07%
|
15.02%
|
6.41%
|
-4.57%
|
-1.32%
|
7.71%
|
8.23%
|
10.79%
|
FCF Conversion (EBITDA)
|
11.13%
|
54.24%
|
32.87%
|
-
|
-
|
30.44%
|
29.53%
|
38.18%
|
FCF Conversion (Net income)
|
25.05%
|
129.7%
|
172.91%
|
-
|
-
|
126.89%
|
88.46%
|
106.47%
|
Dividend per Share
2 |
0.3600
|
0.1700
|
0.3600
|
-
|
-
|
0.0455
|
0.2510
|
0.4626
|
Announcement Date
|
2/27/20
|
2/26/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
2,677
|
2,537
|
1,198
|
1,198
|
2,396
|
1,405
|
1,543
|
2,810
|
1,541
|
1,713
|
3,254
|
1,561
|
1,663
|
3,225
|
1,597
|
1,770
|
1,626
|
1,812
|
3,445
|
1,735
|
1,890
|
EBITDA
1 |
731.4
|
634.5
|
-
|
-
|
327
|
248.2
|
-
|
618.3
|
308
|
294
|
602.7
|
298.8
|
360.7
|
659.5
|
373.6
|
426.3
|
350.4
|
441.3
|
795.9
|
449.6
|
504.8
|
EBIT
1 |
421.7
|
463.6
|
-
|
-
|
131.5
|
-
|
-
|
427.3
|
173.4
|
176.9
|
378.3
|
175.7
|
253.6
|
-
|
264.4
|
329.3
|
203.8
|
324.1
|
-
|
339.5
|
380.2
|
Operating Margin
|
15.75%
|
18.27%
|
-
|
-
|
5.49%
|
-
|
-
|
15.21%
|
11.25%
|
10.33%
|
11.63%
|
11.25%
|
15.25%
|
-
|
16.55%
|
18.61%
|
12.54%
|
17.89%
|
-
|
19.57%
|
20.12%
|
Earnings before Tax (EBT)
1 |
-
|
378.2
|
-
|
-
|
-27.78
|
-
|
-
|
227.9
|
66.69
|
46.88
|
133.4
|
-84.17
|
103.2
|
19.05
|
99.59
|
105.4
|
47.06
|
-
|
-
|
-
|
-
|
Net income
1 |
218.2
|
266.8
|
-
|
-
|
-84.01
|
-
|
-
|
143.6
|
45
|
20.07
|
64.63
|
-108.3
|
52.04
|
-56.22
|
59.54
|
55.99
|
21.42
|
117.5
|
-
|
129.5
|
120
|
Net margin
|
8.15%
|
10.52%
|
-
|
-
|
-3.51%
|
-
|
-
|
5.11%
|
2.92%
|
1.17%
|
1.99%
|
-6.93%
|
3.13%
|
-1.74%
|
3.73%
|
3.16%
|
1.32%
|
6.48%
|
-
|
7.46%
|
6.35%
|
EPS
2 |
-
|
0.3900
|
-0.0600
|
-
|
-0.1200
|
-
|
-
|
0.2100
|
-
|
-
|
0.1000
|
-
|
0.0800
|
-
|
-
|
-
|
0.0665
|
0.1729
|
-
|
0.1906
|
0.1766
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/30/20
|
7/29/21
|
2/28/22
|
2/28/22
|
2/28/22
|
7/28/22
|
7/28/22
|
7/28/22
|
11/8/22
|
2/28/23
|
2/28/23
|
5/9/23
|
7/27/23
|
7/27/23
|
11/2/23
|
2/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
6,465
|
6,436
|
6,695
|
9,158
|
9,337
|
9,333
|
8,806
|
8,308
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
4.595
x
|
4.352
x
|
6.963
x
|
7.501
x
|
6.419
x
|
5.179
x
|
4.147
x
|
3.618
x
|
Free Cash Flow
1 |
157
|
802
|
316
|
-277
|
-87.1
|
549
|
627
|
877
|
ROE (net income / shareholders' equity)
|
15.9%
|
12.5%
|
3.26%
|
3.57%
|
3.72%
|
7.74%
|
11.1%
|
11.8%
|
ROA (Net income/ Total Assets)
|
5.13%
|
4.01%
|
1.06%
|
1.02%
|
1.04%
|
2.09%
|
3.2%
|
3.23%
|
Assets
1 |
12,193
|
15,409
|
17,254
|
20,384
|
5,701
|
20,676
|
22,157
|
25,480
|
Book Value Per Share
2 |
7.050
|
12.00
|
8.950
|
9.040
|
8.640
|
10.10
|
11.10
|
12.30
|
Cash Flow per Share
2 |
0.8300
|
1.620
|
0.8800
|
-0.0200
|
0.3100
|
1.270
|
1.620
|
2.080
|
Capex
1 |
412
|
308
|
281
|
266
|
295
|
560
|
370
|
370
|
Capex / Sales
|
8.09%
|
5.77%
|
5.69%
|
4.39%
|
4.48%
|
7.88%
|
4.85%
|
4.56%
|
Announcement Date
|
2/27/20
|
2/26/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
9.328
EUR Average target price
17.35
EUR Spread / Average Target +86.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -39.64% | 6.12B | | -2.29% | 89.87B | | -3.95% | 37.57B | | -13.07% | 32.75B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B |
Biopharmaceuticals
|